Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 4, 1994 - Issue 11
Submit an article Journal homepage
10
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Overview Cardiovascular & Renal: Recent developments in renin inhibitors: part II

Peter Raddatz E Merck Darmstadt, Department of Medicinal Chemistry, Preclinical Pharmaceutical Research, Frankfurter Str 250, 64271, Darmstadt, Germany
Pages 1347-1359 | Published online: 03 Mar 2008

References to Primarv Literature

  • RADDATZ P: Recent developments in renin inhibitors:part L E:cp. Opin. Then Patents 4 (5): 489–504
  • ABDEL-MEGEU1D SS: Inhibitors of aspartyl proteinases.Med. Res. Rev. (1993) 13: 731–78.
  • FOOTE EF, HALSTENSON LE: New therapeutic agents inthe management of hypertension: angiotensin II-recep-tor antagonists and renin inhibitors. Ann. Pbarmacother. (1993) 27: 1495–1503.
  • DELABAYS A, NUSSBERGER J, PORCHET M, WAEBER B, HOYOS P, BOGER R et al.: Hetaodynarnic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension (1989) 13: 941–7.
  • BURSZTYN M, GAVRAS I, TIFFT CP, BAUER JH, MELBY JC, GAVRAS H: Renin inhibition with A-64662: effect on blood pressure and hormonal response in man. J. Hypertens. (1989) 7 (suppl): S306–7.
  • BURSZTYN M, GAVRAS I, TIFFT CP, LUTHER R, BOGER R, GAVRAS H: Effects of a novel renin inhibitor in patients with essential hypertension. J. Cardiovasc. Pbarmacol. (1990) 15: 493–500.
  • BOGER RS, GLASSMANN HN, CAVANAUGH JH, SCHMITZPJ, LAMM J, MOYSE D et al.: Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension- Hypertension (1990) 15: 835–40.
  • GRIFFTHS AN, NEUTEL JM, GLASSMAN HN, BOGER RS,WEBER MA, LUTHER RR.: The hypotensive effect of Increasing doses of enalkiren, a dipeptide renin inhibi-tor, compared with enalaprilat In hypertensive pa-tients. Br. J. din. Pbarmacol. (1990) 29: 614P–5P.
  • ANDERSON PW, DA YS, SCHAMBELAN M, HORTON R,BOGER RS, LUTHER RR etal.: Effects of renin inhibition In systemic hypertension. Am. J. Cardiol. (1990) 66: 1342–7.
  • WEBER MA, NEUTEL JM, ESSINGER I, GLASSMAN HN, BOGER RS, LUTHER R: Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Cir-culation (1990) 81: 1768–74.
  • NEUTEL JM, LUTHER RR, BOGER RS, WEBER MA: Immedi-ate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme in-hibitor enalaprilat. Am. Heart. J. (1991) 122: 1094–100.
  • GUPTA SK, GRANNEMAN GR, BOGER RS, HOLLENBERG NK, LUTHER RR: Simultaneous modelling of the phar-macokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). b single dose study. Drug Metab. Dispos. (1992) 20: 821–5.
  • GUPTA SK, GRANNEMAN GR, PACKER M, BOGER RS: Simultaneous modelling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662 a renin inhibitor). II: a dose-ranging study in patients with congestive heart failure. J. Cardiovasc. Pbarmacol. (1993) 21: 834–840.
  • FISHER NDL, ALLAN D, KIFOR I, GABOURY CL, WILLIAMS GH, MOORE TJ, HOLLENBERG NK: Response to convert-ing enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension (1994) 23: 44–51.
  • FISCHLI W, CLOZEL JP, AMRANI RE, WOSTL W, NEIDNART W, STADLER H et al: Ro 42-5892 is a potent orally active renin inhibitor in prhnates. Hypertension (1991) 18: 22–31.
  • VAN DEN MELRACKER AH, ADMIRAAL PJJ, MANIN'T VELDAJ, DERKX FHM, RITSEMAvANECK HJ, MULDER P et al.: Prolonged blood pressure reduction by orally active renin inhibitor Ro 42–5892 in essential hypertension. BMJ(1990) 301: 205–10.
  • MENARD J, GUYENE TT, CHATELLIER G, KEINBLOESEMCH, BERNADET P: Renin release regulation during acute renin inhibition in normal volunteers. Hypertension (1991) 18: 257–65.
  • CAMENZIND E, NUSSBERGER J, JUILLERAT L, MUNAFO A,FISCHLI W, COASSOLO P et al.: Effect of the renin re-sponse during renin inhibition: oral Ro 42–5892 in normal humans. J. Cardiovasc. Pharmacol. (1991) 18: 299–307.
  • DOIG JK, MACFADYEN RJ, MEREDITH PA, FISCHLI W, REIDJL: Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. J. Cardiovasc. Pharmacol. (1992) 20: 875–80.
  • KIOWSKI W, LINDER L, KLEINBOESEM C, VAN BRUMME-LEN P, BUHIER FR: Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation (1992) 85: 1–8.
  • CLOZEL JP, FISCH11 W: Discovery of rernikiren as thefirst orally active renin inhibitor. Drug Res. (1993) 43: 260–62.
  • KLEINBOESEM CH, WEBER C, FAHRNER E, DELLENBACH M, WELKER H, SCHROTER V, BELZ GG: Hemodynamics, biochemical effects, and pharmakokinetics of the renin inhibitor remikiren in healthy human subjects. C7in. Pharmacol. Ther. (1993) 53: 585–92.
  • KOBRIN I, VISKOPER RJ, LASZT A, BOCK J, WEBER C,CHARLON V: Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am.J. Hypertens. (1993) 6: 349–356.
  • VAN DEN MEIRACKER AH, ADMIRAAL PJJ, DERIOC FHM,KLEINBOESEM C, MAN IN'T VELD AJ, VAN BRUMMELEN P, MULDER P, SCHALEKAMP MADH: Comparison of blood pressure and angiotensin responses to the renin inhibi-tor Ro 42-5892 and the angiotensin converting enzyme Inhibitor enalapril in essential hypertension. J. Hyper-tension (1993) 11: 831–38.
  • OGIHARA T, NAGANO M, HIGAKI J, H1GASHIMORI K,MASUO K, MIKAMI H: Antihypertensive efficacy of FIC.906, a novel human renin inhibitor. Clinical The. (1993) 15: 539–48.
  • DENOLLE T, LUO P, GUYENE TT, CAZAUBON C, SISSMANNJ, CORVOL P, MENARD J: Acute effects of a pseudo-tetrapeptide as renin inhibitor on blood pressure and renin-angiotensin system of sodium-repleted and so-dium-depleted hypertensive patients. Drug Res. (1993) 43: 255–59.
  • ROSENBERG SH, SPINA ICP, WOODS KW, POLAKOWSKI J,MARTIN DL, YAO Z, STEIN HH, COHEN J, BARLOW JL, EGAN DA, TRICARICO ILK, BAKER WR, KLEINERT HD: Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides. J. Med. Chem. (1993) 36: 449–59.
  • ROSENBERG SH, SPINA KP, CONDON SL, POLAKOWSKI J, YAO Z, KOVAR P, STEIN HH, COHEN J, BARLOW JL, KLINGHOFER V, EGAN DA, TRICARICO KA, PERUN TJ, BAKER WR, KLEINERT HD: Studies directed toward the desing of orally active renin Inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (25)-2-Benzy1-31(1-methylpiperazirt-4-yl)sulfonyl]propionyl ]-3-thiazol-4-yl-L-alanine amide of (2S,3R,45)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptarte (A-72517). J. Med. Chem. (1993) 36: 460–67.
  • WESSALE JL, KLEINERT HD, CALZADILLA SV, KOVAR PJ, ROSENBERG SH: Effects of renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-de-pleted dogs. Am. J. Hypertension. (1993) 6: 514–21.
  • VERBURG KM, POLAKOWSKI JS, KOVAR PJ, KLINGHOFER V, BARLOW JL, STEIN HH, MANTEI RA, FUNG AKL, BOYD SA, BAKER WR, KLEINERT HD: Effects of high doses of A-74273, a novel nonpeptidic and orally bioavailable refs's' inhibitor. J. Cardiovasc. Pharmacol. (1993) 21: 149–55.
  • WESSALE JL, CALZADILLA SV, BOYD SA, BAKER WR, STEINHH, KOVAR PJ, BARLOW J, KLINGHOFER V, MAINTEI R, KLEINERT HD: Cardiovascular effects and hemody-namic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs. J. Cardiovasc. Pharma-col. (1993) 22: 644–52.
  • HEITSCH H, HENNING R, ICLEIMANN HW, LINZ W, NICKEL WV, RUPPERT D, URBACH H, WAGNER A: Renin inhibi-tors containing a pyridyl amino diol derived C-termi-nus. J. Med. Chem. (1993) 36: 2788–2800.
  • LINZ W, HEITSCH H, HENNING R, JUNG W, KLEEMANN I1W, NICKEL WV, RUPPERT D, LTRBACH H, WAGNER A, SCHOLICENS BA: Effects of the renin inhibitor /VIN-(3-(4-ainhio-1-piperidinryl-carbony1)-2(R)-benzylpropio ny1)-L-histidiny11-(25,3R,45)-1-cyclohexyl-3,4-dihydro xy-6(2-pyricly1)-hexane-2-amide acetate in anesthetized rhesus monkeys. Drug Res. (1994) 44(10: 815–820.
  • ETOH Y, MIYAZAKI M, SAITOH H, TODA N: ICRI-1314: an orally effective inhibitor of human renin. Jap. J. Pharmcacol. (1993) 63: 109–119.
  • ICLEINMAN RE, FRAY AH, HOLT WE, KIRON MAR, MURPHY WR, PUCELL IM, ROSATI RE: CP-71,362, an unusually potent inhibitor of rat and dog realm Bioorg. Med. Chem. Lett. (1994) 4(4): 589–92.
  • MENTO PF, MAITA ME, MURPHY WE, HOLT WE, WILKES BM: Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial in-farction. J. Cardiovasc. Pharmacol. (1993) 21: 791–96.
  • RADDATZ P, MINCK KO, RIPPMANN F, SCHMITGES CJ: Non-peptide renin inhibitors containing 24(3-phenyl-propyl)phosphoryDoxy)alkanoic acid moieties as P2-P3 replacements. J. Med. Chem. (1994) 37: 486–97.
  • SMITH SA, AL-BARAZANJI A, BUCKINGHAM RE, CASSIDY F, COLDWELL MC, FINNEY FJL, HADLEY MS, HAM P, NASH LDJ, TINGLEY EJR, WATSON JM: The idenification of a novel renin inhibitor of equivalent efficacy following oral or intravenous administration. Bioorg. Med. Chem. Lett. (1994) 4: 1291–96.
  • POSS MA, REID JA, FREE CA, ROGERS WL, WEBER H, RYONO DE, DEJNEKA T, DEFORREST JM, WALDRON 'a, BRIITAIN RJ, WELLER HN, CIMARUSTI MP, PETRILLO EW: Diol sulfonamides: a potent and novel dass of inhibi-tors of human renin. Bioorg. Med. Chem. Lett. (1993) 3: 2739–44.
  • HURLEY TR, COLSON CR, HICKS G, RYAN MJ: Orally active water-soluble N,0-acyl transfer products of a 13-bishy-droxyl amide containing renin Inhibitor. J. Med. Chem. (1993) 36: 1496–98.
  • RYAN MJ, HICKS GW, BATLEY BL, RAPUNDALO ST, PATT WC, TAYLOR DG, KEISER JA: Effect of an orally active renin Inhibitor CI-992 on blood pressure in normoten- sive and hypertensive monkeys. J. Pbarmacol.Ther.(1994) 268: 372–79. References to Patent Literature

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.